BackPediatrix Medical Group Overview

Pediatrix Medical Group Gross Profit

Latest gross profit for MD: $390M, below the Healthcare sector average of $65B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Gross Profit

$132.47M
↑ 6.21% YoY

As of Jun 30, 2026

Annual Gross Profit (TTM)

$385.78M
↓ 18.39% YoY

Trailing 12 months ending Jun 30, 2026

Average Gross Profit (Comparison Companies)

Gross Profit History

Gross Profit Comparison

Annual Gross Profit Growth Rate (%)

Annual Gross Profit Growth (Absolute)

Pediatrix Medical Group (MD) FAQ

The latest gross profit for MD is $390M as of June 2026. That compares with $470M in the prior-year period — down 18.4% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Pediatrix Medical Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, MD's gross profit moved from $470M to $390M — a 18.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pediatrix Medical Group's operating scale or balance-sheet position.

Against Healthcare companies, MD currently prints $390M for gross profit, while the sector average sits near $65B. That is roughly 99.4% below the sector mean. Large gaps often invite a closer look at Pediatrix Medical Group's growth, margins, and balance sheet.

A gross profit figure of $390M for MD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting MD's gross profit ($390M), review year-over-year change from $470M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.